X

Drug Profile

PSK 3471

Alternative Names: PSK-3471; SERM-3471

Latest Information Update: 17 Mar 2009

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProSkelia; sanofi-aventis
Developer Galapagos NV
Class Osteoporosis therapies
Mechanism of Action Selective estrogen receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Postmenopausal osteoporosis

Most Recent Events

22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
24 Mar 2004 Phase-II clinical trials in Postmenopausal osteoporosis prevention in Europe (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com